The DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders
Open accessAbstract
The field of gene therapy is striving more than ever to define a path to the clinic and the market. Twenty gene therapy products have already been approved and over two thousand human gene therapy clinical trials have been reported world-wide. These advances raise great hope to treat devastating rare and inherited diseases as well as intractable illnesses. Gene therapy is presently starting to become commercially profitable as a number of gene and cell-based gene therapy products have been approved and have entered the market and the clinic. Understanding the precise pathomechanisms of diseases as well as emerging efficient and specific gene targeting and delivery tools are revolutionizing the global market. Currently, human cancers and monogenic disorders are indications number one. The elevated prevalence of genetic disorders and cancers, clear gene manipulation guidelines, as well as increasing financial support for gene therapy in clinical trials are major trends. This article addresses the history and development of twenty approved human gene and cell-based gene therapy products that have been approved up-to-now in clinic and markets of mainly North America, Europe and Asia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Prevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
Terwilliger, T., & Abdul-Hay, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.53 · Cited by 1,288
Morpholino Antisense Oligomers: Design, Preparation, and Properties
SUMMERTON, J., & WELLER, D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,116
Baumgartner, I., Pieczek, A., Manor, O., Blair, R., Kearney, M., Walsh, K., & Isner, J. M. (1998) · Circulation · doi:10.1161/01.cir.97.12.1114 · Cited by 1,098
Finkel, R. S., Chiriboga, C. A., Vajsar, J., Day, J. W., Montes, J., De Vivo, D. C., Yamashita, M., Rigo, F., Hung, G., Schneider, E., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31408-8 · Cited by 1,019
The splice variants of vascular endothelial growth factor (VEGF) and their receptors
Robinson, C. J., & Stringer, S. E. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.5.853 · Cited by 944
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60756-3 · Cited by 878
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Geary, R. S., Norris, D., Yu, R., & Bennett, C. F. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.008 · Cited by 845
Eteplirsen for the treatment of Duchenne muscular dystrophy
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L., Gomez, A. M., Lewis, S., Kota, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23982 · Cited by 817
Oncolytic virus therapy: A new era of cancer treatment at dawn
Fukuhara, H., Ino, Y., & Todo, T. (2016) · Cancer Science · doi:10.1111/cas.13027 · Cited by 774
Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744
TRUCKs: the fourth generation of CARs
Chmielewski, M., & Abken, H. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1046430 · Cited by 738
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., Guglieri, M., Ashton, E., Abbs, S., Nihoyannopoulos, P., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70211-x · Cited by 653
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
Goldberg, A. C., Hopkins, P. N., Toth, P. P., Ballantyne, C. M., Rader, D. J., Robinson, J. G., Daniels, S. R., Gidding, S. S., de Ferranti, S. D., Ito, M. K., et al. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.03.001 · Cited by 622
Senzer, N. N., Kaufman, H. L., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.3675 · Cited by 616
The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration
Wong, T., Chakravarthy, U., Klein, R., Mitchell, P., Zlateva, G., Buggage, R., Fahrbach, K., Probst, C., & Sledge, I. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.008 · Cited by 601
(2007) · doi:10.1289/ehp.9023 · Cited by 591
Hu, J. C. C., Coffin, R. S., Davis, C. J., Graham, N. J., Groves, N., Guest, P. J., Harrington, K. J., James, N. D., Love, C. A., McNeish, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0759 · Cited by 569
Puzanov, I., Milhem, M. M., Minor, D., Hamid, O., Li, A., Chen, L., Chastain, M., Gorski, K. S., Anderson, A., Chou, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1529 · Cited by 562
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
Goldberg, A. C., Hopkins, P. N., Toth, P. P., Ballantyne, C. M., Rader, D. J., Robinson, J. G., Daniels, S. R., Gidding, S. S., de Ferranti, S. D., Ito, M. K., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.04.003 · Cited by 545
Hartmann, J., Schüßler‐Lenz, M., Bondanza, A., & Buchholz, C. J. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607485 · Cited by 532
Gallant, J. E., Moore, R. D., Richman, D. D., Keruly, J., Chaisson, R. E., & Zidovudine Epidemiology Study Group (1992) · Journal of Infectious Diseases · doi:10.1093/infdis/166.6.1223 · Cited by 529
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub3 · Cited by 520
Kaufman, H. L., Kim, D. W., DeRaffele, G., Mitcham, J., Coffin, R. S., & Kim-Schulze, S. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0809-6 · Cited by 518
Mendell, J. R., Goemans, N., Lowes, L. P., Alfano, L. N., Berry, K., Shao, J., Kaye, E. M., Mercuri, E., & for the Eteplirsen Study Group and Telethon Foundation DMD Italian Network (2016) · Annals of Neurology · doi:10.1002/ana.24555 · Cited by 518
Eteplirsen in the treatment of Duchenne muscular dystrophy
Lim, K. R., Maruyama, R., & Yokota, T. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s97635 · Cited by 495
Ciceri, F., Bonini, C., Stanghellini, M. T. L., Bondanza, A., Traversari, C., Salomoni, M., Turchetto, L., Colombi, S., Bernardi, M., Peccatori, J., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70074-9 · Cited by 488
(1992) · New England Journal of Medicine · doi:10.1056/nejm199201233260401 · Cited by 487
Bennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30371-3 · Cited by 461
Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers
Peng, Z. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1016 · Cited by 436
Age-Related Macular Degeneration
Fine, S. L., Berger, J. W., Maguire, M. G., & Ho, A. C. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002173420707 · Cited by 418
Dias, M. F., Joo, K., Kemp, J. A., Fialho, S. L., da Silva Cunha, A., Woo, S. J., & Kwon, Y. J. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.004 · Cited by 413
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404 · cited 1×
“The duration of Glybera efficacy did not rise by the immune suppression (Fine et al., 2000; Gaudet et al., 2013).”
BackgroundNemunaitis, J. J., Ganly, I., Khuri, F. R., Arseneau, J. C., Kuhn, J., McCarty, T. M., Landers, S., Maples, P. B., Romel, L., Randlev, B., et al. (2000) · PubMed · Cited by 404
Treatment of spinal muscular atrophy by sodium butyrate
Chang, J.-G., Hsieh-Li, H.-M., Jong, Y.-J., Wang, N. M., Tsai, C.-H., & Li, H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171105098 · Cited by 404
Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.52 · Cited by 387
A guide to manufacturing CAR T cell therapies
Vormittag, P., Gunn, R., Ghorashian, S., & Veraitch, F. S. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.01.025 · Cited by 383
Brichta, L. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg256 · Cited by 382
Corbacioglu, S., Cesaro, S., Faraci, M., Valteau-Couanet, D., Gruhn, B., Rovelli, A., Boelens, J. J., Hewitt, A., Schrum, J., Schulz, A. S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61938-7 · Cited by 375
Mäkinen, K., Manninen, H., Hedman, M., Matsi, P., Mussalo, H., Alhava, E., & Ylä-Herttuala, S. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0638 · Cited by 374
Chmielewski, M., Hombach, A. A., & Abken, H. (2014) · Immunological Reviews · doi:10.1111/imr.12125 · Cited by 356
Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment
Raal, F. J., & Santos, R. D. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.02.019 · Cited by 349
Principles and Practice of Endocrinology and Metabolism
Berlinger, F. G. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530330072040 · Cited by 345
Richardson, P. G., Riches, M. L., Kernan, N. A., Brochstein, J. A., Mineishi, S., Termuhlen, A. M., Arai, S., Grupp, S. A., Guinan, E. C., Martin, P. L., et al. (2016) · Blood · doi:10.1182/blood-2015-10-676924 · Cited by 336
Dystrophin, its interactions with other proteins, and implications for muscular dystrophy
Ervasti, J. M. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.05.010 · Cited by 324
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
Bommareddy, P. K., Patel, A., Hossain, S., & Kaufman, H. L. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0238-9 · Cited by 322
Suhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., Schmidt, H., Waddington-Cruz, M., Campistol, J. M., Bettencourt, B. R., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0326-6 · Cited by 321
The First Approved Gene Therapy Product for Cancer Ad- p53 (Gendicine): 12 Years in the Clinic
Zhang, W.-W., Li, L., Li, D., Liu, J., Li, X., Li, W., Xu, X., Zhang, M. J., Chandler, L. A., Lin, H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.218 · Cited by 318
Oncorine, the World First Oncolytic Virus Medicine and its Update in China
Liang, M. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009618666171129221503 · Cited by 314
Kohlhapp, F. J., & Kaufman, H. L. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2667 · Cited by 303
Stein, E. A., Dufour, R., Gagne, C., Gaudet, D., East, C., Donovan, J. M., Chin, W., Tribble, D. L., & McGowan, M. (2012) · Circulation · doi:10.1161/circulationaha.112.104125 · Cited by 301
Nusinersen: First Global Approval
Hoy, S. M. (2017) · Drugs · doi:10.1007/s40265-017-0711-7 · Cited by 297
Aiuti, A., Roncarolo, M. G., & Naldini, L. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707573 · Cited by 264
Newborn bloodspot screening for Duchenne Muscular Dystrophy: 21 years experience in Wales (UK)
Moat, S. J., Bradley, D. M., Salmon, R., Clarke, A., & Hartley, L. (2013) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.301 · Cited by 262
Spinal muscular atrophy: a motor neuron disorder or a multi‐organ disease?
Shababi, M., Lorson, C. L., & Rudnik‐Schöneborn, S. S. (2014) · Journal of Anatomy · doi:10.1111/joa.12083 · Cited by 262
Diagnosis and treatment of familial hypercholesterolaemia
Hovingh, G. K., Davidson, M. H., Kastelein, J. J. P., & O'Connor, A. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht015 · Cited by 256
China approves first gene therapy
Pearson, S., Jia, H., & Kandachi, K. (2004) · Nature Biotechnology · doi:10.1038/nbt0104-3 · Cited by 255
Richardson, P. G. G., ELIAS, A. D., Krishnan, A. Y., Wheeler, C., Nath, R., Hoppensteadt, D., Kinchla, N. M., Neuberg, D. S., Waller, E. K., Antin, J. H., et al. (1998) · PubMed · Cited by 254
Thomas, G. S., Cromwell, W. C., Ali, S., Chin, W., Flaim, J. D., & Davidson, M. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.081 · Cited by 245
Xia, Z.-J., Chang, J.-H., Zhang, L., et al. (2004) · PubMed · Cited by 241
Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy
Corey, D. R. (2017) · Nature Neuroscience · doi:10.1038/nn.4508 · Cited by 240
Richardson, P. G., Soiffer, R. J., Antin, J. H., Uno, H., Jin, Z., Kurtzberg, J., Martin, P. L., Steinbach, G., Murray, K. F., Vogelsang, G. B., et al. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.02.009 · Cited by 237
Clinical development of gene therapy: results and lessons from recent successes
Kumar, S. R., Markusic, D. M., Biswas, M., High, K. A., & Herzog, R. W. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.34 · Cited by 232
Crooke, R. M., Graham, M. J., Lemonidis, K. M., Whipple, C. P., Koo, S., & Perera, R. J. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400492-jlr200 · Cited by 225
McGowan, M. P., Tardif, J.-C., Ceska, R., Burgess, L. J., Soran, H., Gouni-Berthold, I., Wagener, G., & Chasan-Taber, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049006 · Cited by 224
(2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01327-2 · Cited by 222
Cicalese, M. P., Ferrua, F., Castagnaro, L., Pajno, R., Barzaghi, F., Giannelli, S., Dionisio, F., Brigida, I., Bonopane, M., Casiraghi, M., et al. (2016) · Blood · doi:10.1182/blood-2016-01-688226 · Cited by 219
Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy
Al‐Zaidy, S., Pickard, A. S., Kotha, K., Alfano, L. N., Lowes, L., Paul, G., Church, K., Lehman, K., Sproule, D. M., Dabbous, O., et al. (2019) · Pediatric Pulmonology · doi:10.1002/ppul.24203 · Cited by 216
Corbacioglu, S., Greil, J., Peters, C., Wulffraat, N., Laws, H. J., Dilloo, D., Strahm, B., Gross-Wieltsch, U., Sykora, K. W., Ridolfi-Lüthy, A., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704329 · Cited by 209
Drolet, D. W., Nelson, J., Tucker, C. E., Zack, P. M., Nixon, K., Bolin, R., Judkins, M. B., Farmer, J. A., Wolf, J. L., Gill, S. C., et al. (2000) · Pharmaceutical Research · doi:10.1023/a:1007657109012 · Cited by 206
Bressler, S. B. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.045 · Cited by 205
Azad, R. F., Driver, V. B., Tanaka, K., Crooke, R. M., & Anderson, K. P. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.9.1945 · Cited by 204
Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Melanoma
Johnson, D. B., Puzanov, I., & Kelley, M. C. (2015) · Immunotherapy · doi:10.2217/imt.15.35 · Cited by 203
Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy
Mendell, J. R., & Lloyd‐Puryear, M. (2013) · Muscle & Nerve · doi:10.1002/mus.23810 · Cited by 202
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials
Mercuri, E., Finkel, R., Montes, J., Mazzone, E. S., Sormani, M. P., Main, M., Ramsey, D., Mayhew, A., Glanzman, A. M., Dunaway, S., et al. (2016) · Neuromuscular Disorders · doi:10.1016/j.nmd.2015.10.006 · Cited by 202
Santos, R. D., Raal, F. J., Catapano, A. L., Witztum, J. L., Steinhagen-Thiessen, E., & Tsimikas, S. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.304549 · Cited by 196
Chopra, R., Eaton, J. D., Grassi, A., Potter, M., Shaw, B., Salat, C., Neumeister, P., Finazzi, G., Iacobelli, M., Bowyer, K., et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02475.x · Cited by 195
Exon skipping therapy for Duchenne muscular dystrophy
Kole, R., & Krieg, A. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.008 · Cited by 192
Lessons learned from the clinical development and market authorization of Glybera
Bryant, L. M., Christopher, D. M., Giles, A. R., Hinderer, C., Rodriguez, J. L., Smith, J. B., Traxler, E. A., Tycko, J., Wojno, A. P., & Wilson, J. M. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.087 · Cited by 189
Fomivirsen – a phosphorothioate oligonucleotide for the treatment of CMV retinitis
de Smet, M. D., Meenken, C., & van den Horn, G. J. (1999) · Ocular Immunology and Inflammation · doi:10.1076/ocii.7.3.189.4007 · Cited by 187
Risk factors in head and neck cancer.
Decker, J. W., & Goldstein, J. C. (1982) · PubMed · Cited by 183
Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition
(2007) · CRC Press eBooks · doi:10.1201/9780849387951 · Cited by 181
Gene therapy for lipoprotein lipase deficiency
Gaudet, D., Méthot, J., & Kastelein, J. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283555a7e · Cited by 178
Adams, D., Suhr, O. B., Dyck, P. J., Litchy, W. J., Leahy, R. G., Chen, J., Gollob, J., & Coelho, T. (2017) · BMC Neurology · doi:10.1186/s12883-017-0948-5 · Cited by 178
Hassan, A., Booth, C., Brightwell, A., Allwood, Z., Veys, P., Rao, K., Hönig, M., Friedrich, W., Gennery, A., Slatter, M., et al. (2012) · Blood · doi:10.1182/blood-2011-12-396879 · Cited by 172
Crooke, S. T., & Geary, R. S. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04469.x · Cited by 171
Risk Factors in Head and Neck Cancer
Decker, J., & Goldstein, J. C. (1982) · New England Journal of Medicine · doi:10.1056/nejm198205133061905 · Cited by 170
Nusinersen for the treatment of spinal muscular atrophy
Chiriboga, C. A. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1364159 · Cited by 162
Anderson, K., Fox, M., Brown‐Driver, V., Martin, M., & Azad, R. F. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.9.2004 · Cited by 153
FDA approves patisiran to treat hereditary transthyretin amyloidosis
Wood, H. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0065-0 · Cited by 145 · cited 1×
“Alnylam Pharmaceuticals, Inc. (Nasdaq), the leading RNAi therapeutics company, developed this lipid complex drug to treat familial amyloid polyneuropathy (FAP) in adults (Wood, 2018).”
BackgroundHettle, R., Corbett, M. S., Hinde, S., Hodgson, R. M., Jones-Diette, J. S., Woolacott, N. F., & Palmer, S. (2017) · Health Technology Assessment · doi:10.3310/hta21070 · Cited by 145
HIV-ASSOCIATED RETINOPATHY IN THE HAART ERA
GOLDBERG, D. E., Smithen, L., Angelilli, A., & Freeman, W. R. (2005) · Retina · doi:10.1097/00006982-200507000-00015 · Cited by 144
Aflibercept for neovascular age-related macular degeneration
Sarwar, S., Clearfield, E., Soliman, M. K., Sadiq, M. A., Baldwin, A. J., Hanout, M., Agarwal, A., Sepah, Y. J., Do, D. V., & Nguyen, Q. D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011346.pub2 · Cited by 142
Singh, N. N., Shishimorova, M., Cao, L., Gangwani, L., & Singh, R. N. (2009) · RNA Biology · doi:10.4161/rna.6.3.8723 · Cited by 139
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL
Roberts, Z. J., Better, M., Bot, A. I., Roberts, M. R., & Ribas, A. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1387905 · Cited by 139
Encyclopedia of Molecular Mechanisms of Disease
Läng, F. (2009) · Springer eBooks · doi:10.1007/978-3-540-29676-8 · Cited by 137
Lü, W., Zheng, S., Li, X.-F., Huang, J.-J., Zheng, X., & Li, Z. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i24.3634 · Cited by 137
The Natural History of Inherited Retinal Dystrophy Due to Biallelic Mutations in the RPE65 Gene
Chung, D. C., Bertelsen, M., Lorenz, B., Pennesi, M. E., Leroy, B. P., Hamel, C., Pierce, E. A., Sallum, J. M. F., Larsen, M., Stieger, K., et al. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.09.024 · Cited by 132
Gendicine: The First Commercial Gene Therapy Product; Chinese Translation of Editorial
Wilson, J. M. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1014 · Cited by 130
Transthyretin familial amyloid polyneuropathy: an update
Planté‐Bordeneuve, V. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8708-4 · Cited by 127
Gene therapy for RPE65-related retinal disease
Miraldi Utz, V., Coussa, R. G., Antaki, F., & Traboulsi, E. I. (2018) · Ophthalmic Genetics · doi:10.1080/13816810.2018.1533027 · Cited by 126
Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation
Chalandon, Y., Roosnek, E. E., Mermillod, B., Newton, A., Ozsahin, H., Wacker, P., Helg, C., & Chapuis, B. (2004) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2004.01.002 · Cited by 126
Yu, R. Z., Lemonidis, K. M., Graham, M. J., Matson, J. E., Crooke, R. M., Tribble, D. L., Wedel, M. K., Levin, A. A., & Geary, R. S. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.005 · Cited by 125
Prodrugs for Gene‐Directed Enzyme‐Prodrug Therapy (Suicide Gene Therapy)
Denny, W. A. (2003) · BioMed Research International · doi:10.1155/s1110724303209098 · Cited by 124
Immune responses to AAV-vectors, the Glybera example from bench to bedside
Ferreira, V., Petry, H., & Salmon, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00082 · Cited by 120
Sun, Y., Grimmler, M., Schwarzer, V., Schoenen, F. J., Fischer, U., & Wirth, B. (2004) · Human Mutation · doi:10.1002/humu.20111 · Cited by 120
Faustinella, F., Chang, A., Biervliet, J. P. V., Rosseneu, M., Vinaimont, N., Smith, L. C., Chen, S. H., & Chan, L. Y. S. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98701-6 · Cited by 118
Reid, T. R., Freeman, S., Post, L. E., McCormick, F. P., & Sze, D. Y. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700819 · Cited by 115
Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis
Butler, J. S., Chan, A., Costelha, S., Fishman, S., Willoughby, J. L. S., Borland, T. D., Milstein, S., Foster, D. J., Gonçalves, P., Chen, Q., et al. (2016) · Amyloid · doi:10.3109/13506129.2016.1160882 · Cited by 113
Mulamba, G. B., Hu, A., Azad, R. F., Anderson, K., & Coen, D. M. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.4.971 · Cited by 112
Gene therapy: evidence, value and affordability in the US health care system
Hampson, G., Towse, A., Pearson, S. D., Dreitlein, W. B., & Henshall, C. (2017) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2017-0068 · Cited by 112
Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug
Ferrua, F., & Aiuti, A. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.175 · Cited by 109
Andre, M. S., Johnson, M. C., Bansal, P. N., Wellen, J. W., Robertson, A. W., Opsahl, A., Burch, P. M., Bialek, P., Morris, C. A., & Owens, J. M. (2017) · Skeletal Muscle · doi:10.1186/s13395-017-0141-y · Cited by 108
Genome Editing Technologies: Defining a Path to Clinic
Corrigan‐Curay, J., O’Reilly, M., Kohn, D. B., Cannon, P. M., Bao, G., Bushman, F. D., Carroll, D., Cathomen, T., Joung, J. K., Roth, D. B., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.54 · Cited by 107
Malone, D. C., Dean, R., Arjunji, R. V., Jensen, I. S., Cyr, P. L., Miller, B., Maru, B. S., Sproule, D. M., Feltner, D. E., & Dabbous, O. H. (2019) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2019.1601484 · Cited by 105
Cherian, J. J., Parvizi, J., Bramlet, D. G., Lee, K.-H., Romness, D. W., & Mont, M. A. (2015) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2015.06.019 · Cited by 104
Gaspar, H. B. (2009) · Biologics · doi:10.2147/btt.s3103 · Cited by 104
Gaudet, D., Stroes, E. S., Méthot, J., Brisson, D., Tremblay, K., Bernelot Moens, S. J., Iotti, G., Rastelletti, I., Ardigo, D., Corzo, D., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.158 · Cited by 100
CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes
Ehrke‐Schulz, E., Schiwon, M., Leitner, T., Dávid, S., Bergmann, T., Liu, J., & Ehrhardt, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-17180-w · Cited by 98
Puzanov, I. J., Milhem, M. M., Andtbacka, R. H. I., Minor, D. R., Hamid, O., Li, A., Chastain, M. A., Gorski, K. S., Anderson, A., Vanderwalde, A. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.9029 · Cited by 88
Deev, R. V., Bozo, I. Y., MZHAVANADZE, N. D., Voronov, D. A., Гавриленко, А. В., Chervyakov, Y. V., Staroverov, I. N., Kalinin, R. E., Швальб, П. Г., & Isaev, A. A. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415574336 · Cited by 83
Chawla, S. P., Chua, V. S., Fernandez, L., Quon, D., Blackwelder, W. C., Gordon, E. M., & Hall, F. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.228 · Cited by 81
Drug safety evaluation of defibrotide
Richardson, P. G. G., Corbacioglu, S., Ho, V. T., Kernan, N. A., Lehmann, L., Maguire, C., Maglio, M. E., Hoyle, M., Sardella, M., Giralt, S., et al. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.749855 · Cited by 80
Rexin-G, a targeted genetic medicine for cancer
Gordon, E. M., & Hall, F. L. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.481666 · Cited by 79
Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist
Bianchi, G., Barone, D., Lanzarotti, E., Tettamanti, R., Porta, R., Moltrasio, D., Cedro, A., Salvetti, L., Mantovani, M., & Prino, G. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90864-e · Cited by 78
Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease
Rao, V. K., Kapp, D., & Schroth, M. K. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.12-a.s3 · Cited by 77
Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives
Chen, G., Zhang, S. J., He, X., Liu, S., Ma, C., & Zou, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s50483 · Cited by 76
Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: Summary and perspective
Smith, A., Oertle, J. C., III, Warren, D., & Prato, D. (2016) · Journal of Cellular Immunotherapy · doi:10.1016/j.jocit.2016.08.001 · Cited by 76
Current Treatment Options in Neurology—SMA Therapeutics
Waldrop, M. A., & Kolb, S. J. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0568-z · Cited by 72
(2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01326-0 · Cited by 72
Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS
Boyer, D., Cowen, S. J., Danis, R. P., Diamond, J. G., Fish, R. H., Goldstein, D. A., Jaffe, G. J., Lalezari, J. P., Lieberman, R. M., Belfort, R., et al. (2002) · Pure Amsterdam UMC · Cited by 68
Eteplirsen Approved for Duchenne Muscular Dystrophy: The FDA Faces a Difficult Choice
Stein, C. A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.188 · Cited by 67
Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS
(2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01332-6 · Cited by 65
Adams, D., Cauquil, C. A., Labeyrie, C., Beaudonnet, G., Algalarrondo, V., & Théaudin, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1145664 · Cited by 64
Ramlogan‐Steel, C. A., Murali, A., Andrzejewski, S., Dhungel, B. P., Steel, J. C., & Layton, C. J. (2018) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13416 · Cited by 62
Cicalese, M. P., Ferrua, F., Castagnaro, L., Rolfe, K., Boever, E. H. D., Reinhardt, R. R., Appleby, J., Roncarolo, M. G., & Aiuti, A. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.022 · Cited by 61
Ricotta, D. N., & Frishman, W. H. (2012) · Cardiology in Review · doi:10.1097/crd.0b013e31823424be · Cited by 60
Deev, R. V., Леонидович, П. И., Bozo, I. Y., & Isaev, A. A. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0210-3 · Cited by 58
Vago, L., Oliveira, G., Bondanza, A., Noviello, M., Soldati, C., Ghio, D., Brigida, I., Greco, R., Stanghellini, M. T. L., Peccatori, J., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405670 · Cited by 53
Adoptive Therapy with CAR Redirected T Cells: The Challenges In Targeting Solid Tumors
Abken, H. (2015) · Immunotherapy · doi:10.2217/imt.15.15 · Cited by 53
Spinraza—a rare disease success story
Prakash, V. (2017) · Gene Therapy · doi:10.1038/gt.2017.59 · Cited by 53
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2016) · Blood · doi:10.1182/blood.v128.22.lba-6.lba-6 · Cited by 51
Spinal Muscular Atrophy Therapeutics: Where do we Stand?
d’Ydewalle, C. V. O., & Sumner, C. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0337-y · Cited by 50
Li, Y., Li, B., Li, C., & Li, L. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.990882 · Cited by 49
Chimeric antigen receptor T-cell therapy for glioblastoma
Rodriguez, A., Brown, C. E., & Badie, B. (2017) · Translational research · doi:10.1016/j.trsl.2017.07.003 · Cited by 48
Marcus, R. E., Davies, A. J., Ando, K., Klapper, W., Opat, S., Owen, C., Phillips, E. H., Sangha, R. S., Schlag, R., Seymour, J. F., et al. (2016) · Blood · doi:10.1182/blood.v128.22.6.6 · Cited by 47
Boyer, D., Cowen, S. J., Danis, R. P., Diamond, J. G., Fish, R. H., Goldstein, D. A., Jaffe, G. J., Lalezari, J. P., Lieberman, R. M., Belfort, R., et al. (2002) · Pure Amsterdam UMC · Cited by 45
Technology evaluation: pegaptanib, Eyetech/Pfizer.
Vinores, S. A. (2003) · PubMed · Cited by 43
Pathotropic nanoparticles for cancer gene therapy Rexin-G™ IV: Three-year clinical experience
Gordon, E. M., Lopez, F., Cornelio, G. H., Lorenzo, C., Levy, J. P., Reed, R. A., Liu, L., Bruckner, H. W., & Hall, F. L. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.5.1053 · Cited by 41
Spinal Muscular Atrophy: Therapeutic Strategies
Castro, D., & Iannaccone, S. T. (2014) · Current Treatment Options in Neurology · doi:10.1007/s11940-014-0316-3 · Cited by 35
Current and Future Treatment Approaches in Transthyretin Familial Amyloid Polyneuropathy
Kerschen, P., & Planté‐Bordeneuve, V. (2016) · Current Treatment Options in Neurology · doi:10.1007/s11940-016-0436-z · Cited by 34
Voretigene Neparvovec: An Emerging Gene Therapy for the Treatment of Inherited Blindness
Patel, U. A., Boucher, M., de Léséleuc, L., & Visintini, S. M. (2016) · Europe PMC (PubMed Central) · Cited by 34
Francischetti, I. M. B., Oliveira, C. J. F., Ostera, G. R., Yager, S. B., Debierre-Grockiego, F., Carregaro, V., Jaramillo-Gutierrez, G., Hume, J. C. C., Jiang, L., Moretz, S. E., et al. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.240291 · Cited by 32
Subcutaneous administration of TC007 reduces disease severity in an animal model of SMA
Mattis, V. B., Fosso, M. Y., Chang, C. T., & Lorson, C. L. (2009) · BMC Neuroscience · doi:10.1186/1471-2202-10-142 · Cited by 31
Locke, F. L., Neelapu, S. S., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.7512 · Cited by 29
Bertini, E., Hwu, W., Reyna, S. P., Farwell, W. R., Gheuens, S., Sun, P., Zhong, Z., & Vivo, D. C. D. (2017) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2017.04.1218 · Cited by 29
Kempen, J. H., Martin, B. K., Wu, A. W., Barron, B., Thorne, J. E., & Jabs, D. A. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00089-7 · Cited by 28
Big win possible for Ionis/Biogen antisense drug in muscular atrophy
Garber, K. (2016) · Nature Biotechnology · doi:10.1038/nbt1016-1002 · Cited by 25
Kato, Z., Okuda, M., Okumura, Y., Arai, T., Teramoto, T., Nishimura, M., Kaneko, H., & Kondo, N. (2009) · Journal of Child Neurology · doi:10.1177/0883073809333535 · Cited by 21
Viral Vectors, Engineered Cells and the CRISPR Revolution
DiCarlo, J. E., Deeconda, A., & Tsang, S. H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63904-8_1 · Cited by 21
Considerations and challenges for patients with refractory and relapsed acute myeloid leukaemia
Kell, J. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.05.025 · Cited by 16
Schuster, S. J., Bishop, M. R., Tam, C. S. L., et al. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.07.213 · Cited by 14
VEGF Inhibition Study in Ocular Neovascularization (VISION): Second Year Efficacy Data
D’Amico, D. J. (2005) · Investigative Ophthalmology & Visual Science · Cited by 11
Bondar, O. V., Shevchenko, V. D., Martynova, A., Salakhieva, D. V., Savina, I. N., Shtyrlin, Y. G., & Abdullin, T. I. (2015) · European Polymer Journal · doi:10.1016/j.eurpolymj.2015.03.042 · Cited by 10
Parodi, M. B., Bartolo, E. D., Bruè, C., Cappello, E., Furino, C., Giuffrida, S., Imparato, M., & Reibaldi, M. (2017) · European Journal of Ophthalmology · doi:10.5301/ejo.5001060 · Cited by 10
Russell, S. R., Bennett, J., Maguire, A. M., & High, K. A. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1508340 · Cited by 10
Veenstra, D. L., Guzauskas, G. F., Villa, K. F., & Boudreau, D. M. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1275652 · Cited by 9
An update on gene therapy for the treatment of lipoprotein lipase deficiency
Wang, H., & Libby, A. E. (2014) · Orphan Drugs Research and Reviews · doi:10.2147/odrr.s39979 · Cited by 4
FDA approves orphan drug for inherited cholesterol disorder
reports, S. (2013) · Cited by 3
Mendell, J. R., Al-Zaidy, S. A., SHELL, R. D., Arnold, W. D., Rodino‐Klapac, L. R., Prior, T. W., Lowes, L. P., Alfano, L. N., Berry, K., Church, K. R., et al. (2017) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2017.04.1216 · Cited by 3
CAR-T: trailblazing the path from clinical development to the clinic
Butera, S. (2018) · Gene Therapy · doi:10.1038/s41434-018-0013-z · Cited by 1 · cited 1×
“…two cell-based gene therapies for the treatment of acute lymphoblastic leukemia (ALL), Approved Human Gene Therapy ProductsShahryari et al. 2 September 2019 | Volume 10 | Article 868Frontiers in Genetics | www.frontiersin.org were also approved by FDA (Butera, 2018; Vormittag et al., 2018).”
Cited by
Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719
Lipid Nanoparticles for Drug Delivery
Xu, L., Wang, X., Liu, Y., Yang, G., Falconer, R. J., & Zhao, C.-X. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100109 · Cited by 545
Non-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects
Zu, H., & Gao, D. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00608-7 · Cited by 475
Viral vector‐based gene therapies in the clinic
Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10258 · Cited by 269
Amyotrophic lateral sclerosis: translating genetic discoveries into therapies
Akçimen, F., Lopez, E. R., Landers, J. E., Nath, A., Chiò, A., Chia, R., & Traynor, B. J. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00592-y · Cited by 234
Metadata
- Authors
- Shahryari, A., Saghaeian Jazi, M., Mohammadi, S., Razavi Nikoo, H., Nazari, Z., Hosseini, E. S., Burtscher, I., Mowla, S. J., & Lickert, H.
- Venue
- Frontiers in Genetics
- Publisher
- Frontiers Media SA
- Published
- 2019-09-25
- Volume
- 10
- Pages
- 868-868
- ISSN
- 1664-8021 (ISSN-L)
- OpenAlex
- W2969783143
- Cited by
- 262
- References
- 184
- FWCI
- 18.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.